• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

December 29, 2015

Study Finds Link between Hepatitis C and Parkinson's Disease

Author(s):

Bill Schu

Study is the first to demonstrate a strong association between HCV and PD.

A Taiwanese study in Neurology suggests that patients who have the hepatitis C virus (HCV) are at a significantly higher risk of developing Parkinson’s disease (PD). The finding is not the first time a link between HCV and brain troubles has surfaced, but it is among the first to demonstrate a strong association between HCV and PD.

The finding is potentially important because of the wide worldwide prevalence of HCV and the fact that PD is a clinically devastating condition for which the etiology is not yet completely understood. Taiwan has high rates of HCV infection.

The current research was a population-based cohort study based on data obtained from a Taiwanese national registry from 2000 to 2010. A total of 49,967 patients with HCV were included for analysis. An additional control population of nearly 200,000 people without HCV were included for comparison. The mean age of the patients was about 46 years, and 43.5% of patients were women. Patients were followed for 12 years.

Patients with viral hepatitis were further grouped into 3 cohorts: hepatitis B virus (HBV) infection, HCV infection, and HBV-HCV coinfection. The researchers calculated the incidence of developing PD in each cohort, using a Cox proportional hazards model to estimate the risk of developing PD.

They found a strong association between HCV infection and developing PD. The crude hazard ration for developing PD was 0.66 (95% CI = 0.55—0.80) for HBV infection, 2.50 (95% CI = 2.07–3.02) for HCV infection, and 1.28 (95% CI = 0.88–1.85) for HBV-HCV coinfection. T

he association between HCV and PD remained statistically significant after adjustments for age, sex, and comorbidities (adjusted HR = 1.29, 95% CI = 1.06—1.56). The results amount to a 2.5-fold increased risk for PD in patients with HCV infection compared with controls (no HCV or HBV) (hazard ratio [HR], 2.5; 95% confidence interval [CI], 2.07 - 3.02).

The adjusted HRs for HBV and coinfection were not statistically significant. But the researchers noted that there were too few patients with PD in the coinfection category to attain statistical significance. Further research will be needed to establish the connection, if any, and shed further light on why HCV can lead to PD.

The theory, according to the study, is that neuro-inflammation triggered because of HCV ultimately leads to PD through a series of cytokines currently under additional study.

Also still to be studied is whether treatment for HCV, which has been revolutionized in recent years, ameliorates the increased risk for PD.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com
Menoapuse spelled with wooden blocks -- Image credit: loran4a | stock.adobe.com
Related Content
Advertisement
FDA Approved Food and Drug Administration concept. Person with FDA icon on virtual screen for Health product standards control system.
June 30th 2025

FDA Approves Emapalumab-Lzsg as First-Ever Treatment for Macrophage Activation Syndrome in Still Disease

Luke Halpern, Assistant Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Creative layout of colorful pills and capsules on blue background. Minimal medical concept. Pharmaceutical, Covid-19 or Coronavirus. Flat lay, top view
June 26th 2025

Mid-Year Roundup: FDA’s Novel Retail and Specialty Drug Approvals in 2025

Luke Halpern, Assistant Editor
Pharmacy Focus: World Psychedelics Day
June 14th 2024

Pharmacy Focus: World Psychedelics Day

Ashley Gallagher, Editor
Pediatric multisystem inflammatory syndrome. kawasaki disease symptoms.
June 23rd 2025

IVIG-Glucocorticoid Combination Therapy Reduces Need for Adjunctive Immunotherapy in Pediatric MIS-C

Luke Halpern, Assistant Editor
FDA Approves Dupilumab for Treatment of Bullous Pemphigoid
June 20th 2025

FDA Approves Dupilumab for Treatment of Bullous Pemphigoid

Aislinn Antrim, Managing Editor
Related Content
Advertisement
FDA Approved Food and Drug Administration concept. Person with FDA icon on virtual screen for Health product standards control system.
June 30th 2025

FDA Approves Emapalumab-Lzsg as First-Ever Treatment for Macrophage Activation Syndrome in Still Disease

Luke Halpern, Assistant Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Creative layout of colorful pills and capsules on blue background. Minimal medical concept. Pharmaceutical, Covid-19 or Coronavirus. Flat lay, top view
June 26th 2025

Mid-Year Roundup: FDA’s Novel Retail and Specialty Drug Approvals in 2025

Luke Halpern, Assistant Editor
Pharmacy Focus: World Psychedelics Day
June 14th 2024

Pharmacy Focus: World Psychedelics Day

Ashley Gallagher, Editor
Pediatric multisystem inflammatory syndrome. kawasaki disease symptoms.
June 23rd 2025

IVIG-Glucocorticoid Combination Therapy Reduces Need for Adjunctive Immunotherapy in Pediatric MIS-C

Luke Halpern, Assistant Editor
FDA Approves Dupilumab for Treatment of Bullous Pemphigoid
June 20th 2025

FDA Approves Dupilumab for Treatment of Bullous Pemphigoid

Aislinn Antrim, Managing Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.